pegtomarginase (PT-01) / Athenex - LARVOL DELTA

PT01: A Phase I Open-label Study for Subjects With Advanced Malignancies (clinicaltrials.gov) - P1; N=62; Recruiting; Sponsor: Athenex, Inc.; Not yet recruiting ➔ Recruiting; Trial completion date: Jan 2021 ➔ Dec 2022; Trial primary completion date: Jan 2021 ➔ Dec 2022

Clinical • Enrollment open • Trial completion date • Trial primary completion date • Oncology • Solid Tumor